SCHEMBL849140

SCHEMBL849140

CC1(C)OC[C@H](COS(C)(=O)=O)O1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 8/20 0.73
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP3A4 P08684 2/20 0.38
CA1 P00915 3/20 0.33
CA9 Q16790 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1222790 1.00 CA2 (0.73) CA2ALDH1A1NPSR1CYP3A4CA1
SCHEMBL1416178 1.00 CA2 (0.73) CA2ALDH1A1NPSR1CYP3A4CA1
SCHEMBL2749426 0.85 CA2 (0.59) CA2ALDH1A1NPSR1CYP3A4CA1
SCHEMBL18063437 0.84 CA2 (1.00) CA2ALDH1A1NPSR1CA1CA9
SCHEMBL18063439 0.84 CA2 (1.00) CA2ALDH1A1NPSR1CA1CA9
SCHEMBL17392767 0.83 CA2 (0.56) CA2ALDH1A1NPSR1CYP3A4KDM4E
SCHEMBL8820316 0.83 CA2 (0.51) CA2CYP3A4
SCHEMBL2077365 0.83 CA2 (0.55) CA2ALDH1A1NPSR1CYP3A4CA1
SCHEMBL1901250 0.83 CA2 (0.55) CA2ALDH1A1NPSR1CYP3A4CA1
SCHEMBL369753 0.83 CA2 (0.55) CA2ALDH1A1NPSR1CYP3A4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312349-B2 Apoptosis-inducing agents FOCHON PHARMACEUTICALS, LTD. (CN) 2025-05-27 US disclosed
EP-4119560-B1 APOPTOSIS-INDUCING AGENTS FOCHON PHARMACEUTICALS LTD (CN) 2024-06-05 EP disclosed
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers iTeos Belgium SA (BE) 2023-05-25 US disclosed
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers iTeos Belgium SA (BE) 2023-05-25 US disclosed
EP-4119560-A1 APOPTOSIS-INDUCING AGENTS Shanghai Fochon Pharmaceutical Co., Ltd. (CN) 2023-01-18 EP disclosed
EP-4112623-A1 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS iTeos Belgium SA (BE) 2023-01-04 EP disclosed
EP-4112623-A1 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS iTeos Belgium SA (BE) 2023-01-04 EP disclosed
US-20220402913-A1 APOPTOSIS-INDUCING AGENTS FOCHON PHARMACEUTICALS, LTD. (CN) 2022-12-22 US disclosed
EP-3612531-B1 APOPTOSIS-INDUCING AGENTS SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) 2022-08-24 EP disclosed
EP-3601296-B1 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS iTeos Belgium SA (BE) 2022-05-25 EP disclosed
EP-0249610-B1 SYNTHESIS OF OPTICALLY ACTIVE ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-08-25 EP disclosed
EP-0322390-B1 NOVEL ANTIARRHYTHMIC AGENTS I Aktiebolaget Hässle (SE) 1992-11-11 EP disclosed
US-5155133-A Antiarrhythmic compounds and pharmaceutical compositions and methods thereof AKTIEBOLAGET HASSLE (SE) 1992-10-13 US disclosed
US-5010198-A Intermediates for the synthesis of benzoxazol- and benzothiazolamine derivatives, useful as anti-anoxic agents JANSSEN PHARMACEUTICA N.V. (BE) 1991-04-23 US disclosed
US-4990668-A Reacting selected dioxolane with hydrohalic acid and organic acid, then with amine E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-02-05 US disclosed
EP-0184257-B1 BENZOXAZOL- AND BENZOTHIAZOLAMINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1990-07-25 EP disclosed
US-4861785-A Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic agents JANSSEN PHARMACEUTICA N.V. (BE) 1989-08-29 US disclosed
WO-1989005794-A1 NOVEL ANTIARRHYTHMIC AGENTS I Aktiebolaget Hässle (SE) 1989-06-29 WO disclosed
EP-0322390-A2 Novel antiarrhythmic agents I Aktiebolaget Hässle (SE) 1989-06-28 EP disclosed
EP-0184257-A1 Benzoxazol- and benzothiazolamine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1986-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402913-A1 APOPTOSIS-INDUCING AGENTS BCL2, BAX, BAD CA2 3261/4885ALDH1A1 3024/4885NPSR1 4768/4885
US-12312349-B2 Apoptosis-inducing agents BCL2, BAX, BAD CA2 3261/4885ALDH1A1 3024/4885NPSR1 4768/4885
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers ADORA2A, ADORA2B, ADORA3 CA2 793/4885ALDH1A1 123/4885NPSR1 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.